Herzinsuffizienz bei Menschen mit Diabetes mellitus

ZUSAMMENFASSUNG

Die Herzinsuffizienz stellt eine wichtige Komorbidität bei Patienten mit Diabetes mellitus dar. Das Vorliegen beider Erkrankungen verschlechtert die Prognose der Patienten maßgeblich. Daher ist eine frühzeitige Diagnose und effiziente Therapie beider Erkrankungen immens wichtig. Die vorliegende Arbeit gibt einen Überblick über die Diagnose und Therapie der Herzinsuffizienz und erläutertet die Besonderheiten, auf die bei Patienten mit Diabetes mellitus geachtet werden sollte.

Publication History

Article published online:
19 August 2022

• Literatur

• 1 McDonagh TA, Metra M, Adamo M. et al 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
• 2 Shah AD, Langenberg C, Rapsomaniki E. et al Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol 2015; 03: 105-113
• 3 Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015; 36: 1718-1727 1727a–1727c
• 4 Sattar N, McGuire DK. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink. Circulation 2018; 138: 7-9
• 5 Nichols GA, Hillier TA, Erbey JR. et al Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614-1619
• 6 Adler AI, Stratton IM, Neil HA. et al Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Bmj 2000; 321: 412-419
• 7 Bertoni AG, Hundley WG, Massing MW. et al Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703
• 8 Carr AA, Kowey PR, Devereux RB. et al Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005; 96: 1530-1536
• 9 Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. Jama 1979; 241: 2035-2038
• 10 Gottdiener JS, Arnold AM, Aurigemma GP. et al Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-1637
• 11 van Melle JP, Bot M, de Jonge P. et al Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care 2010; 33: 2084-2089
• 12 Nichols GA, Gullion CM, Koro CE. et al The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884
• 13 Boonman-de Winter LJ, Rutten FH, Cramer MJ. et al High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012; 55: 2154-2162
• 14 Zareini B, Rørth R, Holt A. et al Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. Cardiovasc Diabetol 2019; 18: 79
• 15 [Anonym]. Centers for Disease Control and Prevention. Incidence of Newly Diagnosed Diabetes. Accessed February 2022 https://www.cdc.gov/diabetes/data/statistics-report/newly-diagnosed-diabetes.html
• 16 Dauriz M, Targher G, Laroche C. et al Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 2017; 40: 671-678
• 17 Targher G, Dauriz M, Laroche C. et al In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 54-65
• 18 McMurray JJ, Packer M, Desai AS. et al Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004
• 19 Dauriz M, Targher G, Temporelli PL. et al Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc 2017: 6
• 20 Cavender MA, Steg PG, Smith Jr. SC. et al Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015; 132: 923-931
• 21 Johansson I, Dahlström U, Edner M. et al Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. J Am Coll Cardiol 2016; 68: 1404-1416
• 22 Kristensen SL, Jhund PS, Lee MMY. et al Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovasc Drugs Ther 2017; 31: 545-549
• 23 MacDonald MR, Petrie MC, Varyani F. et al Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385
• 24 Kristensen SL, Mogensen UM, Jhund PS. et al Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation 2017; 135: 724-735
• 25 Yusuf S, Pfeffer MA, Swedberg K. et al Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781
• 26 Crespo-Leiro MG, Anker SD, Maggioni AP. et al European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18: 613-625
• 27 Bozkurt B, Coats AJS, Tsutsui H. et al Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021; 23: 352-380
• 28 Madamanchi C, Alhosaini H, Sumida A. et al Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol 2014; 176: 611-617
• 29 Ponikowski P, Voors AA, Anker SD. et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975
• 30 Butler J, Anker SD, Filippatos G. et al Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. Eur Heart J 2021; 42: 4887-4890
• 31 McMurray JJV, Solomon SD, Inzucchi SE. et al Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008
• 32 Docherty KF, Jhund PS, Bengtsson O. et al Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care 2020; 43: 2878-2881
• 33 Packer M, Anker SD, Butler J. et al Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424
• 34 Anker SD, Butler J, Filippatos G. et al Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation 2021; 143: 337-349
• 35 Zannad F, Ferreira JP, Pocock SJ. et al SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819-829
• 36 Bhatt DL, Szarek M, Steg PG. et al Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2021; 384: 117-128
• 37 [Anonym] The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435
• 38 Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. Jama 1995; 273: 1450-1456
• 39 Gustafsson I, Torp-Pedersen C, Køber L. et al Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999; 34: 83-89
• 40 Moyé LA, Pfeffer MA, Wun CC. et al Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994; 15 Suppl B: 2-8; discussion 26-30
• 41 Shekelle PG, Rich MW, Morton SC. et al Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538
• 42 Kristensen SL, Preiss D, Jhund PS. et al Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016: 9
• 43 Seferovic JP, Claggett B, Seidelmann SB. et al Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2017; 05: 333-340
• 44 [Anonym] Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007
• 45 Packer M, Coats AJ, Fowler MB. et al Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658
• 46 Packer M, Bristow MR, Cohn JN. et al The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355
• 47 [Anonym] The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
• 48 Bobbio M, Ferrua S, Opasich C. et al Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Card Fail 2003; 09: 192-202
• 49 Deedwania PC, Giles TD, Klibaner M. et al Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149: 159-167
• 50 Erdmann E, Lechat P, Verkenne P. et al Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 03: 469-479
• 51 Packer M, Fowler MB, Roecker EB. et al Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199
• 52 Hirst JA, Farmer AJ, Feakins BG. et al Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. British journal of clinical pharmacology 2015; 79: 733-743
• 53 Pitt B, Zannad F, Remme WJ. et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
• 54 Zannad F, McMurray JJ, Krum H. et al Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
• 55 Bristow MR, Saxon LA, Boehmer J. et al Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150
• 56 Ghali JK, Boehmer J, Feldman AM. et al Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 2007; 13: 769-773
• 57 Køber L, Thune JJ, Nielsen JC. et al Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375: 1221-1230
• 58 Rørth R, Thune JJ, Nielsen JC. et al The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace 2019; 21: 1203-1210
• 59 Glikson M, Nielsen JC, Kronborg MB. et al 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). European Heart Journal 2021; 42: 3427-3520 %J European Heart Journal
• 60 Anker SD, Butler J, Filippatos G. et al Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385: 1451-1461